Intuitive Surgical Inc SEC Filings

Intuitive Surgical (ISRG) reported strong Q3 2025 results. Revenue rose to $2,505.1M from $2,038.1M a year ago, led by instruments and accessories $1,518.8M, systems $590.4M, and service $395.9M. Net income was $704.4M with diluted EPS of $1.95 (vs. $1.56), and income from operations reached $759.7M. U.S. revenue was $1,717.6M; outside the U.S. was $787.5M.

Cash and cash equivalents were $2,806.6M and short‑term investments $2,102.2M as of September 30, 2025. Year‑to‑date cash from operations was $2,138.0M. The company repurchased $1,919.6M of stock in Q3 at an average price of $479.60; authorization remaining was about $1.9B. Remaining performance obligations were $2.88B. Intuitive outlined a pending acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino for EUR 290M upfront plus up to EUR 31M in milestones, subject to approvals and expected in the first half of 2026.

Legal updates included an appeals court affirming a prior judgment in the Rex Medical matter and a trial court ruling in Intuitive’s favor on SIS antitrust claims; a related class action was certified, with no trial date set.

Intuitive Surgical (ISRG) furnished an 8-K announcing quarterly results. On October 21, 2025, the company issued a press release with financial results for the quarter ended September 30, 2025, attached as Exhibit 99.1. The materials are furnished and not deemed filed under the Exchange Act.

Gary Loeb, EVP & Chief Legal and Compliance at Intuitive Surgical (ISRG), reported beneficial ownership changes on 10/10/2025. A vesting event converted 2,612 restricted stock units into common shares (transaction code M), with net shares deposited after withholding for taxes. Immediately following the vesting, the filing shows a sale/disposition of 1,296 shares at $443.76 (transaction code F), leaving the reporting person with 3,561 shares beneficially owned. The RSU grant vests 25% annually over four years, and the filing notes that 25% of the grant was released at this vesting date.

Amy L. Ladd, a director of Intuitive Surgical, reported two scheduled sales of common stock under a Rule 10b5-1 trading plan that expires on June 4, 2026. She sold 336 shares on 09/03/2025 at an average price of $470.11 and 335 shares on 09/04/2025 at an average price of $440.69. After the transactions she beneficially owned 1,074 shares following the first sale and 739 shares following the second sale. The filing is a Form 4 disclosure of changes in beneficial ownership and indicates the trades were made pursuant to a pre-established trading plan.

Intuitive Surgical Inc. (ISRG) Form 144 shows a proposed sale of 335 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $147,631.15, targeted for 09/04/2025. The shares were acquired as restricted stock on 04/25/2024 from the issuer. The filer represents no undisclosed material information. The filing also reports a separate sale by Amy L. Ladd of 336 shares on 09/03/2025 for $157,956.96. The issuer's reported shares outstanding are 358,476,506, indicating these transactions represent a very small fraction of total equity.

Intuitive Surgical (ISRG) filed a Form 144 reporting a proposed sale of 336 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/03/2025. The filing lists an aggregate market value of $157,956.96 and shows 358,476,506 shares outstanding. The shares to be sold were originally issued as restricted stock: 102 shares acquired 04/27/2023 and 234 shares acquired 04/25/2024; payment is listed as Not Applicable. The filing reports no securities sold during the past three months. Several administrative fields (filer CIK/CCC and issuer contact details) are not populated in the provided text.

Insider transactions by Gary S. Guthart, Executive Chair of Intuitive Surgical (ISRG). On 08/29/2025 Mr. Guthart acquired 36,000 shares via exercise of a non-qualified stock option at an exercise price of $79.6378 and sold 29,360 shares at a weighted average price of $472.4873 under a pre-existing Rule 10b5-1 trading plan that expires April 28, 2026. After these transactions he directly beneficially owned 49,187 shares and holds additional indirect ownership through family trusts totaling 1,241,843 shares combined. The option vests partly six months after grant with further monthly vesting and expires 02/15/2027. The Form 4 was signed on 09/02/2025.

Form 144 filing for Intuitive Surgical, Inc. (ISRG) shows a proposed sale of 29,360 common shares to be executed through Morgan Stanley Smith Barney on 08/29/2025, with an aggregate market value of $13,872,227.13. The shares were acquired the same day by stock option exercise and paid for in cash. The filing identifies prior sales during the past three months by Gary S. Guthart totaling 10,693 shares on 07/28/2025 for gross proceeds of $5,329,417.02. The filer affirms they are not aware of any undisclosed material adverse information and includes the standard Rule 10b5-1/trading-plan notice language.

Form 4 details insider activity at Intuitive Surgical (ISRG) on 28 Jul 2025 by Executive Chair Gary S. Guthart:

• Option exercise: 7,893 non-qualified options exercised at $59.4622.
• Open-market sales: Same 7,893 shares sold at a weighted-avg $498.64 (~$3.9 m). Two family trusts each sold 1,400 shares at ~$495, adding ≈$1.4 m.
• Charitable gift: 10,500 shares transferred to a Donor-Advised Fund (price reported $0).

After the transactions Guthart holds 13,187 shares directly and ~1.24 m shares indirectly through trusts, maintaining a large economic stake. All trades were executed under a Rule 10b5-1 plan expiring 28 Apr 2026, suggesting pre-scheduled diversification rather than a sudden sentiment shift.